Based: Morrisville, NC
Investors: Essex Woodland Health Ventures, Investor Growth Capital, General Catalyst Partners, De Novo Ventures, Spray Ventures Partners and Quaker Bioventures
Scoop: TearScience gathered $44.5 million in a single Series C venture capital deal on May 5. The company plans to use the funds to commercialize diagnostic and treatment devices for dry eye syndrome. Their LipiFlow device has been approved in Europe, but is awaiting an FDA nod.